Brain permeability of bilobalide as probed by microdialysis before and after middle cerebral artery occlusion in mice

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 4, 2010, Pages 607-614

  Lang, Dorothee ^a   Ude, Christian ^a   Wurglics, Mario ^a   Schubert Zsilavecz, Manfred ^a   Klein, Jochen ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILOBALIDE; NEUROTRANSMITTER RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CONTROLLED STUDY; CORPUS STRIATUM; DIALYSATE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; FEMALE; GINKGO BILOBA; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICRODIALYSIS; MIDDLE CEREBRAL ARTERY OCCLUSION; MOLECULAR INTERACTION; MOUSE; NEUROPROTECTION; NONHUMAN; STROKE;

EID: 79951789938     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j31c7q     Document Type: Article

References (28)

1. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch. Neurol. 1998; 55: 1409-1415.
2. Ramassamy C, Longpre F, Chrsiten Y. Ginkgo biloba extract (EGb 761) in Alzheimer ́s disease: is there any evidence? Curr. Azheimer Res. 2007; 4: 253-262.
3. Pierre S, Jamme I, Droy-Lefaix MT, Nouvelot A, Maixent JM. Ginkgo biloba extract (EGb 761) protects Na,K-ATPase activity during cerebral ischemia in mice. Neuroreport 1999; 10: 47-51.
4. Chandrasekaran K, Mehrabian Z, Spinnewyn B, Drieu K, Fiskum G. Neuroprotective effects of bilobalide, a component of the Ginkgo biloba extract (EGb 761), in gerbil global brain ischemia. Brain Res. 2001; 922: 282-292.
5. Paganelli RA, Benetoli A, Milani H. Sustained neuroprotection and facilitation of behavioral recovery by the Ginkgo biloba extract, EGb 761, after transient forebrain ischemia in rats. Behav. Brain Res. 2006; 174: 70-77.
6. Klein J, Chatterjee SS, Loffelholz K. Phospholipid breakdown and choline release under hypoxic conditions: inhibition by bilobalide, a constituent of Ginkgo biloba. Brain Res. 1997; 755: 347-350.
7. Weichel O, Hilgert M, Chatterjee SS, Lehr M, Klein J. Bilobalide, a constituent of Ginkgo biloba, inhibits NMDA-induced phospholipase A2 activation and phospholipid breakdown in rat hippocampus. Naunyn Schmiedebergs Arch. Pharmacol. 1999; 360: 609-615.
8. Mdzinarishvili A, Kiewert C, Kumar V, Hillert M, Klein J. Bilobalide prevents ischemiainduced edema formation in vitro and in vivo. Neuroscience 2007; 144: 217-222.
9. Kiewert C, Kumar V, Hildmann O, Rueda M, Hartmann J, Naik RS, Klein J. Role of GABAergic antagonism in the neuroprotective effects of bilobalide. Brain Res. 2007; 1128: 70-78.
10. Kiewert C, Kumar V, Hildmann O, Hartmann J, Hillert M, Klein J. Role of glycine receptors and glycine release for the neuroprotective activity of bilobalide. Brain Res. 2008; 1201: 143-150.
11. Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cell. Mol. Life Sci. 2003; 60: 1779-1792.
12. Abdel-Kader R, Hauptmann S, Keil U, Scherping I, Leuner K, Eckert A, Müller WE. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol. Res. 2007; 56: 493-502.
13. Biber A. Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry 2003; 36 Suppl 1: S32-S37.
14. Mauri P, Simonetti P, Gardana C, Minoggio M, Morazzoni P, Bombardelli E, Pietta P. Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts. Rapid Commun. Mass Spectrom. 2001; 15: 929-934.
15. Kressmann S, Müller WE, Blume HH. Pharmaceutical quality of different Ginkgo biloba brands. J. Pharm. Pharmacol. 2002; 54: 661-669.
16. Woelkart K, Feizlmayr E, Dittrich P, Beubler E, Pinl F, Suter A, Bauer R. Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother. Res. 2010; 24: 445-450.
17. Mauri P, Minoggio M, Iemoli L, Rossoni G, Morazzoni P, Bombardelli E, Pietta P. Liquid chromatography/atmospheric pressure chemical ionization ion trap mass spectrometry of terpene lactones in plasma of animals. J. Pharm. Biomed. Anal. 2003; 32: 633-639.
18. Ude C, Paulke A, Noldner M, Schubert-Zsilavecz M, Wurglics M. Plasma and Brain Levels of Terpene Trilactones in Rats after an Oral Single Dose of Standardized Ginkgo biloba Extract EGb 761(R). Planta Med. 2010; epub DOI: 10.1055/s-0030-1250286.
19. Rangel-Ordonez L, Noldner M, Schubert-Zsilavecz M, Wurglics M. Plasma Levels and Distribution of Flavonoids in Rat Brain after Single and Repeated Doses of Standardized Ginkgo biloba Extract EGb 761(R). Planta Med. 2010; 76: 1683-1690.
20. Kiewert C, Mdzinarishvili A, Hartmann J, Bickel U, Klein J. Metabolic and transmitter changes in core and penumbra after middle cerebral artery occlusion in mice. Brain Res. 2010; 1312: 101-107.
21. Mdzinarishvili A, Geldenhuys WJ, Abbruscato TJ, Bickel U, Klein J, Van der Schyf CJ. NGP1- 01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia. Neurosci. Lett. 2005; 383: 49-53.
22. DeFeudis FV. Bilobalide and neuroprotection. Pharmacol. Res. 2002; 46: 565-568.
23. Huang SH, Duke RK, Chebib M, Sasaki K, Wada K, Johnstob GA. Bilobalide, a sesquiterpene trilactone from Ginkgo biloba, is an antagonist at recombinant a1ß2g2L GABAA receptors. Eur. J. Pharmacol. 2003; 464: 1-8.
24. Ivic L, Sands TT, Fishkin N, Nakanishi K, Kriegstein AR, Stromgaard K. Terpene trilactones from Ginkgo biloba are antagonists of cortical glycine and GABAA receptors. J. Biol. Chem. 2003; 278: 49279-49285.
25. Van Beek TA. Ginkgolides and bilobalide: their physical, chromatographic and spectroscopic properties. Bioorg. Med. Chem. 2005; 13: 5001-5012.
26. Madgula VL, Avula B, Yu YB, Wang YH, Tchantchou F, Fisher S, Luo Y, Khan IA, Khan SI. Intestinal and blood-brain barrier permeability of ginkgolides and bilobalide: in vitro and in vivo-approaches. Planta Med. 2010; 76: 599-606.
27. Krieglstein J, Ausmeier F, Elabhar H, Lippert K, Welsch M, Rupalla K, Henrich-Noack P. Neuroprotective effects of Ginkgo biloba constituents. Eur. J. Pharm. Sci. 1995; 3: 39-48.
28. Davies JA, Johns L, Jones FA. Effects of bilobalide on cerebral amino acid neurotransmission. Pharmacopsychiatry 2003; 36 Suppl 1: S84-S88.